Viking Therapeutics

Historical price data

Viking Therapeutics is a US-based, publicly-traded biotech focused on developing innovative small-molecule drugs for metabolic diseases. Its core achievement is advancing VK2735, a dual GLP-1/GIP agonist, into a Phase 3 obesity program with both subcutaneous and oral formulations, demonstrating significant weight loss in mid-stage trials. The company's strategy leverages deep expertise in hormone receptor pharmacology to create differentiated therapies with potential advantages over existing incretin-based treatments. With a market cap of approximately $3.63 billion, Viking has captured substantial investor interest as a key player in the next generation of obesity therapeutics.

A proprietary platform focused on advanced hormone receptor pharmacology, specializing in the design of dual and selective receptor agonists (e.g., GLP-1/GIP) and formulation science for both injectable and oral delivery.

Viking competes directly with Eli Lilly's approved dual GLP-1/GIP agonist, tirzepatide, and other incretin-based therapies from Novo Nordisk and a host of clinical-stage biotechs. Its small-molecule approach and development of an oral formulation are key differentiators in this crowded and high-stakes field.